Retrovirus vector production and transduction: modulation by the cell cycle

References

1. Abonour R., Williams D. A., Einborn L. 15 other authors 2000; Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells. Nat Med 6:652–658
   [Google Scholar]
2. Agarwal M., Austin T. W., Morel F., Chen J., Bohnlein E., Plavec I. 1998; Scaffold attachment region-mediated enhancement of retroviral vector expression in primary T cells. J Virol 72:3720–3728
   [Google Scholar]
3. Andreadis S. T., Brott D., Fuller A. O., Palsson B. O. 1997; Moloney murine leukemia virus-derived retroviral vectors decay intracellularly with a half-life in the range of 5·5 to 7·5 hours. J Virol 71:7541–7548
   [Google Scholar]
4. Dando J. S., Aiuti A., Deola S., Ficara F., Bordignon C. 2001; Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34⁺ cells. J Gene Med 3:219–227
   [Google Scholar]
5. Dick J. E. 2000; Gene therapy turns the corner. Nat Med 6:624–626
   [Google Scholar]
6. Dolnikov A., Millington M., Sun L.-Q., Symonds G. 2000; Induced p21 ^WAF1 expression acts to reverse myc myelomonocytic cell transformation. Cancer Gene Ther 7:1491–1503
   [Google Scholar]
7. Frisa P. S., Jacobberger J. W. 2002; Cell density related gene expression: SV40 large T antigen levels in immortalized astrocyte lines. BMC Cell Biol 3:10
   [Google Scholar]
8. Goh W. C., Rogel M. E., Kinsey C. M., Michael S. F., Fultz P. N., Nowak M. A., Hahn B. H., Emerman M. 1998; HIV-1 Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo . Nat Med 4:65–71
   [Google Scholar]
9. Hawley R. G., Lieu F. H., Fong A. Z., Hawley T. S. 1994; Versatile retroviral vectors for potential use in gene therapy. Gene Ther 1:136–138
   [Google Scholar]
10. Holt S. E., Aisner D. L., Shay J. W., Wright W. E. 1997; Lack of cell cycle regulation of telomerase activity in human cells. Proc Natl Acad Sci U S A 94:10687–10692
    [Google Scholar]
11. Huberman J. A. 1981; New views of the biochemistry of eucaryotic DNA replication revealed by aphidicolin, an unusual inhibitor of DNA polymerase alpha. Cell 23:647–648
    [Google Scholar]
12. Karn J., Watson J. V., Lowe A. D., Green S. M., Vedeckis W. 1989; Regulation of cell cycle duration by c- myc levels. Oncogene 4:773–787
    [Google Scholar]
13. Lewis P. F., Emerman M. 1994; Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 68:510–516
    [Google Scholar]
14. Maio J. J., Graham G. J., Brown F. L. 1995; Induction of G₂ arrest and gene expression by 2-aminopurine in human U937 promonocytic-macrophage cells. Exp Cell Res 219:442–448
    [Google Scholar]
15. Malech H. L. 2000; Use of serum-free medium with fibronectin fragment enhanced transduction in a system of gas permeable plastic containers to achieve high levels of retrovirus transduction at clinical scale. Stem Cells 18:155–156
    [Google Scholar]
16. McTaggart S., Al-Rubeai M. 2000; Effects of culture parameters on the production of retroviral vectors by human packaging cell line. Biotechnol Prog 16:859–865
    [Google Scholar]
17. Miller A. D. 1992; Retroviral vectors. Curr Top Microbiol Immunol 158:1–24
    [Google Scholar]
18. Miller D. G., Adam M. A., Miller A. D. 1990; Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 10:4239–4242 erratum 12, 433
    [Google Scholar]
19. Morgan J. R., Ledoux J. M., Snow R. G., Tompkins R. G., Yarmush M. L. 1995; Retrovirus infection: effect of time and target cell number. J Virol 69:6994–7000
    [Google Scholar]
20. Moritz T., Dutt P., Xiao X., Carstanjen D., Vik T., Hanenberg H., Williams D. A. 1996; Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. Blood 88:855–862
    [Google Scholar]
21. Pear W. S., Nolan G. P., Scott M. L., Baltimore D. 1993; Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci U S A 90:8392–8396
    [Google Scholar]
22. Pollok K. E., van Der Loo J. C., Cooper R. J. 8 other authors 2001; Differential transduction efficiency of SCID-repopulating cells derived from umbilical cord blood and granulocyte colony-stimulating factor-mobilized peripheral blood. Hum Gene Ther 12:2095–2108
    [Google Scholar]
23. Reeves L., Smucker P., Cornetta K. 2000; Packaging cell line characteristics and optimizing retroviral vector titer: the National Gene Vector Laboratory experience. Hum Gene Ther 11:2093–2103
    [Google Scholar]
24. Roe T., Reynolds T. C., Yu G., Brown P. O. 1993; Integration of murine leukemia virus DNA depends on mitosis. EMBO J 12:2099–2108
    [Google Scholar]
25. Romano G., Pacilio C., Giordano A. 1999; Gene transfer technology in therapy: current applications and future goals. Stem Cells 17:191–202
    [Google Scholar]
26. Shounan Y., Dolnikov A., MacKenzie K. L., Miller M., Chan Y. Y., Symonds G. 1996; Retroviral transduction of hematopoietic progenitor cells with mutant p53 promotes survival and proliferation, modifies differentiation potential and inhibits apoptosis. Leukemia 10:1619–1628
    [Google Scholar]
27. Sladek T. L., Jacobberger J. W. 1998; Cell cycle analysis of retroviral vector gene expression during early infection. Cytometry 31:235–241
    [Google Scholar]
28. Traycoff C. M., Orazi A., Ladd A. C., Rice S., McMahel J., Srour E. F. 1998; Proliferation-induced decline of primitive hematopoietic progenitor cell activity is coupled with an increase in apoptosis of ex vivo expanded CD34⁺ cells. Exp Hematol 26:53–62
    [Google Scholar]
29. Williams C. D., Linch D. C., Watts M. J., Thomas N. S. 1997; Characterization of cell cycle status and E2F complexes in mobilized CD34⁺ cells before and after cytokine stimulation. Blood 90:194–203
    [Google Scholar]
30. Xu R., Reems J. A. 2001; Umbilical cord blood progeny cells that retain a CD34⁺ phenotype after ex vivo expansion have less engraftment potential than unexpanded CD34⁺ cells. Transfusion 41:213–218
    [Google Scholar]
31. Zieve G. W., Turnbull D., Mullins J. M., McIntosh J. R. 1980; Production of large numbers of mitotic mammalian cells by use of the reversible microtubule inhibitor nocodazole. Nocodazole accumulated mitotic cells. Exp Cell Res 126:397–405
    [Google Scholar]